Login to Your Account



Idenix Lands Blockbuster Deal With Novartis Around Antivirals

By Aaron Lorenzo


Thursday, March 27, 2003
By all indications, it looks as if Idenix Pharmaceuticals Inc. has caught the eye of its new neighbor, Novartis Pharma AG, which is taking a controlling interest in Idenix and its viral drug programs through a deal that could be worth up to at least $862 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription